Bli medlem
Bli medlem

Du är här

2019-12-20

AstraZeneca: AstraZeneca divests rights to Arimidex and Casodex in Europe and certain additional countries

Sale to Juvisé Pharmaceuticals supports AstraZeneca's strategy of
focusing on pipeline of new medicines

AstraZeneca today announced that it has agreed to sell the commercial
rights to Arimidex (anastrozole) and Casodex (bicalutamide) in a
number of European, African and other countries[1] to Juvisé
Pharmaceuticals.

The medicines, used primarily to treat breast and prostate cancers,
have lost their compound patent protection in these countries.
AstraZeneca already divested the rights to both Arimidex and Casodex
in the US in 2017.

Dave Fredrickson, Executive Vice President, Oncology Business Unit,
said: "Arimidex and Casodex are important established medicines and
we are pleased that Juvisé Pharmaceuticals will now take on the work
of making sure patients continue to have access to them. Today's
agreement is part of a broader strategy of reducing our portfolio of
mature medicines to reallocate resources towards developing our
pipeline of new medicines."

Financial considerations

As there were no closing conditions to the divestment, the agreement
became effective upon signing. Juvisé Pharmaceuticals has made an
upfront payment of $181m to AstraZeneca and may also make future
sales-contingent payments of up to $17m. Income arising from the
upfront payment will be reported in AstraZeneca's financial
statements in the fourth quarter of 2019. Income from the upfront and
any future payments will be reported within Other Operating Income &
Expense. In 2018, Arimidex had sales of $37m in the countries covered
by this agreement, while Casodex had sales of $24m. The divestment
does not change the Company's financial guidance for 2019.

About Arimidex

Arimidex (anastrozole) is an aromatase inhibitor, indicated primarily
for the adjuvant treatment of postmenopausal women with hormone
receptor-positive early breast cancer, the first-line treatment of
postmenopausal women with hormone receptor-positive or hormone
receptor-unknown locally advanced or metastatic breast cancer and the
treatment of advanced breast cancer in postmenopausal women with
disease progression, following tamoxifen therapy.

About Casodex

Casodex (bicalutamide) is an androgen-receptor inhibitor, indicated
for use in combination therapy with a luteinising hormone-releasing
hormone analogue for the treatment of Stage D2 metastatic carcinoma
of the prostate.

About AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery, development
and commercialisation of prescription medicines, primarily for the
treatment of diseases in three therapy areas - Oncology,
Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca
operates in over 100 countries and its innovative medicines are used
by millions of patients worldwide. Please visit astrazeneca.com
(http://www.astrazeneca.com/) and follow the Company on Twitter
@AstraZeneca (https://twitter.com/AstraZeneca).

Media Relations
Gonzalo Viña +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Jennifer Hursit Other +44 203 749 5762
Christina Sweden +46 8 552 53 106
Malmberg
Hägerstrand
Michele Meixell US +1 302 885 2677

Investor
Relations
Thomas Kudsk +44 203 749 5712
Larsen
Henry Wheeler Oncology +44 203 749 5797
Christer BioPharmaceuticals +44 203 749 5711
Gruvris (Cardiovascular, Metabolism)
Nick Stone BioPharmaceuticals (Renal) +44 203 749 5716
Environmental, Social and
Governance
Josie Afolabi BioPharmaceuticals +44 203 749 5631
(Respiratory) Other medicines
Craig Marks Finance Fixed income +44 7881 615 764
Jennifer Corporate access Retail +44 203 749 5824
Kretzmann investors
US toll-free +1 866 381 72 77

References

1. For Arimidex and Casodex: Albania, Austria, Belgium, Bulgaria,
Croatia, Cyprus, Estonia, Finland, France, France exports[2],
Germany, Greece, Ireland, Israel, Italy, Liechtenstein, Luxembourg,
Monaco, the Netherlands, Norway, Romania, Serbia, Slovenia, Spain,
Sweden, Switzerland, Algeria, Morocco, Lebanon, Tunisia, Turkey, and
French-speaking Africa (Ivory Coast, Benin, Gabon, Niger, Mauritania,
Burkina Faso, Mali, Chad, Burundi, Cameroon, Guinea, Senegal, Central
African Republic, Togo, Djibouti, Democratic Republic of the Congo,
Republic of the Congo and Madagascar). Additionally, for Arimidex:
Czech Republic, Hungary, Lithuania, Malta, Poland and Portugal.

2. France exports are sales made in France, under the French entity
of AstraZeneca, for export to French DOM-TOMs (Départements
d'outre-mer, Territoires d'outre-mer): DOM-TOMs are either `overseas
collectives' (administrative divisions of France) or `overseas
departments' (officially part of France), and include: French Guyana,
French Polynesia, Guadeloupe, Mayotte, Martinique, New Caledonia, La
Reunion, Saint-Barthelemy, Saint-Martin, Saint-Pierre-et-Miquelon and
Wallis-et-Futuna.

-----------------------------------------------------------
https://news.cision.com/se/astrazeneca/r/astrazeneca-divests-rights-to-a...

Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.